Literature DB >> 26893828

Pim-1 kinase as cancer drug target: An update.

Yernar Tursynbay1, Jinfu Zhang2, Zhi Li3, Tursonjan Tokay4, Zhaxybay Zhumadilov4, Denglong Wu5, Yingqiu Xie1.   

Abstract

Proviral integration site for Moloney murine leukemia virus-1 (Pim-1) is a serine/threonine kinase that regulates multiple cellular functions such as cell cycle, cell survival, drug resistance. Aberrant elevation of Pim-1 kinase is associated with numerous types of cancer. Two distinct isoforms of Pim-1 (Pim-1S and Pim-1L) show distinct cellular functions. Pim-1S predominately localizes to the nucleus and Pim-1L localizes to plasma membrane for drug resistance. Recent studies show that mitochondrial Pim-1 maintains mitochondrial integrity. Pim-1 is emerging as a cancer drug target, particularly in prostate cancer. Recently the potent new functions of Pim-1 in immunotherapy, senescence bypass, metastasis and epigenetic dynamics have been found. The aim of the present updated review is to provide brief information regarding networks of Pim-1 kinase and focus on its recent advances as a novel drug target.

Entities:  

Keywords:  Pim-1; drug target; mitochondrial Pim1; update

Year:  2015        PMID： 26893828      PMCID： PMC4734217          DOI： 10.3892/br.2015.561

Source DB:  PubMed          Journal:  Biomed Rep        ISSN： 2049-9434


  66 in total

1.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.

Authors:  Y Xie; K Xu; B Dai; Z Guo; T Jiang; H Chen; Y Qiu
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

2.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Authors:  Abhinav Kumar; Valsan Mandiyan; Yoshihisa Suzuki; Chao Zhang; Julie Rice; James Tsai; Dean R Artis; Prabha Ibrahim; Ryan Bremer
Journal:  J Mol Biol       Date:  2005-04-22       Impact factor: 5.469

3.  Foxp3 protein stability is regulated by cyclin-dependent kinase 2.

Authors:  Peter A Morawski; Parul Mehra; Chunxia Chen; Tricia Bhatti; Andrew D Wells
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

4.  Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.

Authors:  Yingqiu Xie; Mehmet Burcu; Douglas E Linn; Yun Qiu; Maria R Baer
Journal:  Mol Pharmacol       Date:  2010-05-11       Impact factor: 4.436

5.  The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Authors:  Bo Cen; Ying Xiong; Jin H Song; Sandeep Mahajan; Rachel DuPont; Kristen McEachern; Daniel J DeAngelo; Jorge E Cortes; Mark D Minden; Allen Ebens; Alice Mims; Amanda C LaRue; Andrew S Kraft
Journal:  Mol Cell Biol       Date:  2014-04-28       Impact factor: 4.272

6.  Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.

Authors:  Bo Cen; Sandeep Mahajan; Wenxue Wang; Andrew S Kraft
Journal:  Cancer Res       Date:  2013-04-12       Impact factor: 12.701

7.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Authors:  J Wang; J Kim; M Roh; O E Franco; S W Hayward; M L Wills; S A Abdulkadir
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

8.  Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.

Authors:  Yunsong Tong; Kent D Stewart; Sheela Thomas; Magdalena Przytulinska; Eric F Johnson; Vered Klinghofer; Joel Leverson; Owen McCall; Niru B Soni; Yan Luo; Nan-horng Lin; Thomas J Sowin; Vincent L Giranda; Thomas D Penning
Journal:  Bioorg Med Chem Lett       Date:  2008-08-28       Impact factor: 2.823

9.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

Authors:  Chunaram Choudhary; Jesper V Olsen; Christian Brandts; Jürgen Cox; Pavankumar N G Reddy; Frank D Böhmer; Volker Gerke; Dirk-E Schmidt-Arras; Wolfgang E Berdel; Carsten Müller-Tidow; Matthias Mann; Hubert Serve
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

Review 10.  Suppression, subversion and escape: the role of regulatory T cells in cancer progression.

Authors:  K Oleinika; R J Nibbs; G J Graham; A R Fraser
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330
View more
  28 in total

1.  Reduced pim-1 expression increases chemotherapeutic drug sensitivity in human androgen-independent prostate cancer cells by inducing apoptosis.

Authors:  Xing Zhang; Yuyan Sun; Peng Wang; Changfu Yang; Shengwei Li
Journal:  Exp Ther Med       Date:  2019-08-07       Impact factor: 2.447

Review 2.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

3.  Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.

Authors:  Aaron R Tipton; Geoffrey O Nyabuto; Jill A Trendel; Travis M Mazur; John P Wilson; Suzan Wadi; Jacob S Justinger; Garret L Moore; Peter T Nguyen; Deborah J Vestal
Journal:  Biochem Biophys Res Commun       Date:  2016-08-31       Impact factor: 3.575

Review 4.  A systematic review on active sites and functions of PIM-1 protein.

Authors:  Youyi Zhao; Aziz Ur Rehman Aziz; Hangyu Zhang; Zhengyao Zhang; Na Li; Bo Liu
Journal:  Hum Cell       Date:  2022-01-09       Impact factor: 4.174

5.  A candidate triple-negative breast cancer vaccine design by targeting clinically relevant cell surface markers: an integrated immuno and bio-informatics approach.

Authors:  Shashank Kumar; Mohd Shuaib; Kumari Sunita Prajapati; Atul Kumar Singh; Princy Choudhary; Sangeeta Singh; Sanjay Gupta
Journal:  3 Biotech       Date:  2022-02-20       Impact factor: 2.406

Review 6.  Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma.

Authors:  Ulrich H Weidle; Simon AuslÄnder; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

7.  STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.

Authors:  Daniel Ribeiro; Alice Melão; Ruben van Boxtel; Cristina I Santos; Ana Silva; Milene C Silva; Bruno A Cardoso; Paul J Coffer; João T Barata
Journal:  Blood Adv       Date:  2018-09-11

Review 8.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

9.  Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC.

Authors:  Gillian Moore; Clara Lightner; Samira Elbai; Lauren Brady; Siobhan Nicholson; Ronan Ryan; Katie E O'Sullivan; Kenneth J O'Byrne; Carmen Blanco-Aparicio; Sinead Cuffe; Michael O'Neill; Susan Heavey; Stephen P Finn; Kathy Gately
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

Review 10.  Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy.

Authors:  Alexandru A Sabo; Maria Dudau; George L Constantin; Tudor C Pop; Christoph-M Geilfus; Alessio Naccarati; Mihnea P Dragomir
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.